Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients

Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.

Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.

Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.

Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.